Related Experiment Videos
Geoepidemiology and changing mortality in primary biliary cholangitis
Annarosa Floreani1, Atsushi Tanaka2, Christopher Bowlus3
1Department of Surgery, Oncology and Gastroenterology, University of Padova, via Giustiniani, 2, Padova, Italy.
Journal of Gastroenterology
|April 3, 2017
Summary
Primary biliary cholangitis (PBC) diagnosis and treatment have advanced significantly. Early detection and ursodeoxycholic acid therapy improve survival rates for PBC patients.
Area of Science:
- Hepatology
- Immunology
- Gastroenterology
Background:
- Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease.
- Historically, PBC was diagnosed late and associated with poor prognosis.
- Advancements in diagnostics and therapies have improved patient outcomes.
Purpose of the Study:
- To review the evolution of primary biliary cholangitis diagnosis and management.
- To highlight the impact of early detection and ursodeoxycholic acid therapy.
- To discuss current treatment challenges and future directions in PBC research.
Main Methods:
- Review of historical data and current literature on primary biliary cholangitis.
- Analysis of diagnostic advancements, including antimitochondrial antibody testing.
- Evaluation of therapeutic strategies, focusing on ursodeoxycholic acid and emerging treatments.
Main Results:
- Early diagnosis of PBC is now possible, significantly improving patient survival.
- Ursodeoxycholic acid therapy has transformed PBC-related mortality.
- Approximately 30% of patients show incomplete response to current therapies.
Conclusions:
- PBC management has shifted from a fatalistic view to improved outcomes with early intervention.
- New therapies like obeticholic acid offer promise for non-responsive patients.
- Further research into PBC etiology and personalized medicine is crucial for optimizing patient care.